Company "Rafarma Pharmaceuticals Inc."
Combined Financial statements for the period ended,
June 30, 2022
Company Rafarma Pharmaceuticals Inc.
BALANCE SHEETS
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivables
Short-term investments
VAT Recoverable
Inventories
Other current assets
Total current assets
Research and Development Property, plant, and equipment
Medical equipment for lease Long-term investments
Deferred tax assets
Other non-current assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payables
Short-term borrowings
Other liabilities
Total current liabilities
Long-term borrowings
Deferred Tax Liabilities
Other long-term liabilities
Total liabilities
Stockholders' equity:
Common stock, $0.001 par value per share; 975,000,000 shares authorized; 87,766,999 shares issued and outstanding Preference share capital; $0.001 par value per share; 11,600,000 shares issued and outstanding
Retained earnings
Other Stockholder equity
Total liabilities and stockholders' equity
Notes
4
4
June 30, | December | December | ||||
2022 | 31, 2021 | 31, 2020 | ||||
USD | USD ('000) | USD ('000) | ||||
('000) | ||||||
17,118 | 13,596 | 5,440 | ||||
23,134 | 20,268 | 23,681 | ||||
83 | 27 | 677 | ||||
20 | 50 | 77 | ||||
33,922 | 21,302 | 13,617 | ||||
- | - | 217 | ||||
74,277 | 55,243 | |||||
1,413 | 881 | |||||
49,931 | 28,468 | 22,243 | ||||
- | - | - | ||||
3,435 | 2,396 | 2,300 | ||||
635 | 403 | 283 | ||||
2,622 | 1,953 | 1,689 | ||||
132,313 | 89,344 | 70,634 | ||||
18,828 | 17,224 | 17,499 | ||||
1,055 | 1,612 | 30 | ||||
419 | 219 | - | ||||
20,302 | 19,054 | 17,529 | ||||
663 | 89 | 466 | ||||
2,544 | 696 | 544 | ||||
- | 0 | 0 | ||||
3,207 | 784 | 1,010 | ||||
88 | 88 | 88 | ||||
12 | 12 | 12 | ||||
76,908 | 47,509 | 29,961 | ||||
31,796 | 21,900 | 22,035 | ||||
108,804 | 69,506 | 52,095 | ||||
132,313 | 89,344 | 70,634 |
The accompanying notes are an integral part of these financial statements.
Company Rafarma Pharmaceuticals Inc.
STATEMENTS OF INCOME
Notes | |
Sales revenue | |
Cost of sales | |
Gross profit | |
Selling and marketing expenses | |
Operating expenses | |
Operating income | |
Net gain from interest | |
Net (loss) / gain from other sources | |
Income before taxes | |
Provision for income taxes | |
Net income (loss) | |
Net income per share - basic | 4 |
Net income per share - diluted | 4 |
Weighted average shares outstanding used in per common share computations:
Basic
Diluted
Period ended | Period ended | |
June 30, 2022 | June 30, 2021 | |
USD ('000) | USD ('000) | |
46,126 | 34,101 | |
(29,896) | (21,401) | |
16,230 | 12,700 | |
(3,069) | (3,402) | |
(7,785) | (2,744) | |
5,377 | 6,554 | |
526 | (5) | |
(0,129) | (161,000) | |
5,773 | 6,388 | |
(1,207) | (1,298) | |
4,566 | 5,040 | |
0.0520 | 0.0580 | |
0.0520 | 0.0580 |
87,766,999 87,766,999
87,766,999 87,766,999
The accompanying notes are an integral part of these financial statements.
Company Rafarma Pharmaceuticals Inc.
STATEMENTS OF STOCKHOLDERS' EQUITY
Share | Preference | Other Stockholder Equity | Retained | Total | ||||||||
capital | share | Other | Revaluation of | Additional | Capital | earnings | equity | |||||
capital | Equity | non-current | Capital | reserves | ||||||||
assets | ||||||||||||
As | of | 31 | Amount in USD ('000) | |||||||||
December, | 2020 | |||||||||||
(Un-audited) | 88 | 12 | 8,857 | 665 | 12,198 | 315 | 29,961 | 52,095 | ||||
Net income | 11,573 | 11,573 | ||||||||||
Currency | ||||||||||||
revaluation reserve | (50) | (19) | (68) | (2) | 9,395 | 9,258 | ||||||
Contributions to the | ||||||||||||
reserves | - | - | - | - | - | - | - | - | ||||
Dividends | (3,420) | (3,420) | ||||||||||
As | of | 31 | ||||||||||
December, | 2021 | |||||||||||
(Un-audited) | 87 | 12 | 8,807 | 645 | 12,130 | 313 | 47,509 | 69,504 | ||||
Net income | 4,566 | 4,566 | ||||||||||
Currency | 3,983 | 291 | 5,485 | 142 | 24,834 | 34,734 | ||||||
revaluation reserve | ||||||||||||
Contributions to the | ||||||||||||
reserves | - | - | - | - | - | - | - | - | ||||
Dividends | ||||||||||||
As of 30 June, | 87 | 12 | 12,790 | 936 | 17,615 | 455 | 76,909 | 108,804 | ||||
2022 (Un-audited) |
The accompanying notes are an integral part of these financial statements.
Company Rafarma Pharmaceuticals Inc.
STATEMENTS OF CASH FLOWS
(Unaudited) | |||
Period ended | Year Ended | ||
June 30, | December 31, | ||
2022 | 2021 | ||
Operating activities | USD ('000) | USD ('000) | |
Net income | 4,566 | 11,573 | |
Adjustments to net income: | |||
Unrealized foreign exchange rate differences | 36,774 | 12,304 | |
Income Tax | (1,207) | (3,014) | |
Changes in operating assets and liabilities (net of | |||
acquired assets and liabilities): | |||
Changes in inventories | (12,621) | (7,685) | |
Changes in trade and other receivables | (2,866) | 3,413 | |
Changes in short term investments | (56) | 650 | |
Changes in VAT | 30 | 27 | |
Changes in trade and other payables | 1,605 | (275) | |
Changes in short term borrowings | (557) | 1,582 | |
Changes in other current assets | 0 | 217 | |
Changes in other liabilities | 201 | 219 | |
Net cash provided by operating activities | |||
25,868 | 19,010 | ||
Investing Activities | |||
Sale / purchase of property, plant, and equipment | (21,995) | (6,697) | |
Sale of asset subject finance lease | - | ||
Disposal of other non-current assets | (669) | (264) | |
Net cash used in investing activities | (22,664) | (6,960) | |
Financing Activities | |||
Disposal / (acquisition) of long-term investment | (1,039) | (96) | |
Payment of long-term borrowings | 575 | (377) | |
Payment of dividends | 782 | (3,420) | |
Net cash used in financing activities | 318 | (3,893) | |
Increase (decrease) in cash and cash equivalents | 3,522 | 8,156 | |
Cash and cash equivalents at beginning of year | 13,596 | 5,440 | |
Cash and cash equivalents at end of year | 17,118 | 13,596 |
The accompanying notes are an integral part of these financial statements.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Rafarma Pharmaceuticals Inc. published this content on 15 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 August 2022 18:03:09 UTC.